0001127602-24-000978.txt : 20240105
0001127602-24-000978.hdr.sgml : 20240105
20240105171158
ACCESSION NUMBER: 0001127602-24-000978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240105
DATE AS OF CHANGE: 20240105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelly Jason R
CENTRAL INDEX KEY: 0001845677
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40097
FILM NUMBER: 24517472
MAIL ADDRESS:
STREET 1: 667 MADISON AVENUE
STREET 2: C/O CORVEX MANAGEMENT LP
CITY: NEW YORK
STATE: NY
ZIP: 10065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc.
CENTRAL INDEX KEY: 0001830214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 872652913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (877) 442-5362
MAIL ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20210210
FORMER COMPANY:
FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20201027
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-01-03
0001830214
Ginkgo Bioworks Holdings, Inc.
DNA
0001845677
Kelly Jason R
C/O GINKGO BIOWORKS HOLDINGS
27 DRYDOCK AVENUE
BOSTON
MA
02210
1
1
See remarks
1
Class A Common Stock
2024-01-03
4
S
0
100000
1.544
D
3994680
D
Class A Common Stock
2024-01-04
4
S
0
100000
1.555
D
3894680
D
The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
CEO & Founder
/s/ Karen Tepichin, Attorney-in-Fact
2024-01-05